Can­cer drug de­vel­op­ers will learn from the blaz­ing speed of the Covid-19 vac­cine race, FDA lead­ers say

The whole world watched in awe as the first two Covid-19 vac­cines quick­ly made their way through clin­i­cal tri­als, of­fered stel­lar ef­fi­ca­cy re­sults and were quick­ly ush­ered across the FDA fin­ish line in record time.

As a re­sult, lead­ers of the FDA’s On­col­o­gy Cen­ter of Ex­cel­lence wrote re­cent­ly in the Can­cer Jour­nal that now is the time to lever­age the lessons learned from that high-speed race and trans­late them in­to new op­por­tu­ni­ties for fu­ture on­col­o­gy drug de­vel­op­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER